A study in the Journal of the American Chemical Society reports steps toward making inhalable mRNA medicines a possibility.

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Comprehensive coverage of the hexavalent vaccine can protect again whooping cough and polio writes Esther Nakkazi.

While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...

We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people ... i BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. ii BEYFORTUS® ...

All growth rates mentioned below are on a year-on-year basis and at CER. Sanofi’s Biopharma segment includes Pharma and Vaccines. Biopharma sales rose 16.6% in the quarter to €12.17 billion. Pharma ...

As usual, you can find the slides on sanofi.com. Please turn to Slide number ... now reaching close to EUR3.5 billion in the ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

Sanofi’s Biopharma segment includes Pharma and Vaccines. Biopharma sales rose 16.6% in the quarter to €12.17 billion. Pharma sales increased 13.0% in the quarter to €8.37 billion ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent. Earnings per share excluding some items reached 2.86 euros (S$4.08) in the ...

Investing.com -- Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...